ПОИСК ПО САЙТУ 
поиск по ресурсному центру Since now only the latest non-interferon therapy for the treatment of chronic HCV will be prescribed to all patients in Latvia.
This decision of the National Health Service was published on the LATVIJAS VĒSTNESIS website. The document notes that, since February 1, the treatment regimen for patients with all HCV genotypes will be changed if the disease has progressed to 3-rd or 4-th stage liver fibrosis (F3, F4).
It is noteworthy that according to earlier reports, the cost of medications for the treatment of patients with hepatitis C in Latvia is fully reimbursed since January 1, 2016. Nevertheless, until now some patients continued to receive combined interferon-containing treatment.
Aleksandrs Molokovskis, Chairman of the Board of the HIV.LV Association”:
“Since February 1 in Latvia, chronic HCV of all genotypes in the F3-F4 fibrosis stages will be treated only with a non-interferon regimen – a Gilead medication Epclusa (Sofosbuvir/Velpatasvir) is included in the reimbursement list (to compare costs, the baseline price for reimbursement is EUR 15487 per package of 28 pills, the retail pharmacy price is EUR 17352 for 4 weeks’ course). The resolution part of the decision of the National Health Service, available at https://www.vestnesis.lv/op/2018/22.11), envisages that 10% of the base price will be covered by the applicant, Central Pharma Communications distributor company”.
Hepatitis C in the 3-rd or 4-th stage (F3, F4) is characterized by the extremely serious liver damage – patients already have cirrhosis or fibrosis which is rapidly progressing to cirrhosis, and they should receive therapy as soon as possible.
